FCF Biotech
Venture Capital Monitor

The FCF Biotech Venture Capital Monitor – USA is a monthly published overview of venture capital trends in the US-Biotech sector.

FCF Biotech Venture Capital Monitor - USA

As of the end of June 2023, we identify the following current VC trends in the US-Biotech sector:

  • In 2023, overall Biotech funding in the USA has reached USD 9,562m
  • Compared to June 2022 the financing volume decreased twofold (20,106m vs. 9,562m)
  • Oncology dominates as the top indication
  • Upstream Bio has the highest transaction Volume of USD 200m in June, followed by Alkeus Pharmaceuticals USD 150m and Bitterroot Bio USD 145m
  • ARCH Venture Partners (USA) is leading the Top 5 Investors (by deal volume), followed by Alexandria Venture Investments (USA) and Google Ventures (USA)
  • The top 5 deals exceed USD 190m each, largest transaction amounted to USD 401m in ElevateBio

Capital Markets Research

We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications: